Monetisation in the medical marketing sector
First written in FY2023. 5 of 13 entries say "Restated". Latest entry: 2026-11-13.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「The marketing business consists of 2 areas, the “marketing area” and the “medical area.”」
The company positions the medical marketing area as the medical area and reconfirms its 2-area structure together with the beauty marketing area. - FY2026-H1RestatedAnnual report
「The marketing business consists of 2 areas, the “beauty marketing area” and the “medical marketing area.” The details of each area are as follows. <Beauty Marketing> Marketing support primarily for client companies in the beauty category <Medical Marketing> Marketing support and operational DX support for private-pay clinics」
The company reconfirms its 2-area structure, comprising the beauty marketing area and the medical marketing area, and the services provided in each area. - FY2025WorsenedAnnual report
「However, the plan was reviewed because transactions outside the beauty area declined more than expected and monetization of the medical marketing area was delayed.」
The company explicitly states that monetization of the medical marketing area has been delayed, identifying this as a factor behind the review of its previous medium-term management plan. - FY2024AdvancedAnnual report
「We recognize the launch and monetization of new businesses as challenges in establishing the next pillar of earnings for our group. We will continue to make active business investments toward monetizing the medical marketing area, which we began operating in earnest from the current consolidated fiscal year.」
The company states for the full fiscal year that the medical marketing area began full-scale operations in the fiscal year ending March 2024 and indicates that it will continue making active business investments toward monetization. - FY2024-Q3RestatedAnnual report
「From the fiscal year ending March 2024, the Company has pursued business selection and concentration in the Marketing Business and operates two business areas: the Beauty Marketing area, which provides social media marketing support to corporate clients in the beauty category, and the Medical Marketing area, which provides marketing and operational DX support to beauty clinics and develops and sells products exclusive to clinics.」
The company reconfirms its policy of operating across 2 areas, beauty marketing and medical marketing, from the fiscal year ending March 2024. - FY2024-Q2RestatedAnnual report
「From the fiscal year ending March 2024, the Company has pursued business selection and concentration in the Marketing Business and operates two business areas: the Beauty Marketing area, which provides social media marketing support to corporate clients in the beauty category, and the Medical Marketing area, which provides marketing and operational DX support to beauty clinics and develops and sells products exclusive to clinics.」
The company reconfirms its policy of operating across 2 areas, beauty marketing and medical marketing, from the fiscal year ending March 2024. - FY2024-Q1RestatedAnnual report
「From the fiscal year ending March 2024, the Company has pursued business selection and concentration in the Marketing Business and operates two business areas: the Beauty Marketing area, which provides social media marketing support to corporate clients in the beauty category, and the Medical Marketing area, which provides marketing and operational DX support to beauty clinics and develops and sells products exclusive to clinics.」
The company reconfirms its policy of operating across 2 areas, including the medical marketing area, from the fiscal year ending March 2024, but has not presented any new figures for progress toward the monetization target in the current quarter. - FY2023First statedAnnual report
「We recognize the launch and monetization of new businesses as challenges in establishing the next pillar of earnings for our group. From the fiscal year ending March 2024, we will work toward monetizing the medical marketing area.」
The company newly identifies the medical marketing area as its next pillar of earnings and states its target of working toward monetization from the fiscal year ending March 2024.